Global Ganja Report

Advocates increasingly assert that cannabis legalization is not fully realized unless workers are guaranteed their right to employment even if they partake of the herb off-hours. Some states are finally taking measures to rein in the use of urine-test results as an excuse to fire or turn down job applicants.

In Washington state, glitches in the "seed-to-sale" tracking system nearly paralyzed the cannabis industry statewide last month, costing retailers hundreds of thousands of dollars and forcing temporary lay-offs of employees. Similar headlines have been seen from across the country's legalized states—pointing to a persistent issue.

Two years after legalizing, Nevada has become the first state to bar employers from discriminating against job applicants on the basis of a positive test for cannabis. Will other states follow the lead of the libertarian-spirited Silver State?

China's ambition to get in on the "cannabis boom," providing hemp for the global CBD market, is now making international headlines. But marijuana is more harshly proscribed in China than just about any other country in the world, and the People's Republic continues to execute thousands every year for drug crimes.

Idaho is considering legislation that would raise the number of signatures needed to get an initiative on the ballot—in an apparent bid to undercut a medical marijuana legalization effort. Local activists with the Idaho Cannabis Coalition are saying the law would be "tyranny."

After what has been an agonizing delay for many patients, Louisiana's first medical marijuana harvest has just cleared inspection. But there are still more hurdles before the first extracts and tinctures will begin arriving in the state's nine approved pharmacies. 

With cannabis now legal in 10 US states as well as Canada, demands are growing to wipe out past convictions for personal possession. Politicians have started to respond—but not fast enough for some advocates.

Last month, the DEA enthused the pharmaceutical industry but disappointed cannabis advocates by re-scheduling the drug Epidiolex—but not CBD, the cannabinoid that makes it work. Now word emerges of a letter to the DEA by the Food & Drug Administration essentially calling for the descheduling of CBD altogether.